PEDIATRIC AND YOUNG ADULT NASOPHARYNGEAL CARCINOMA PATIENTS TREATED WITH PRERADIATION CISPLATIN AND DOCETAXEL CHEMOTHERAPY

Basit Öğe Kaydı
dc.contributor.authorVaran, Ali
dc.contributor.authorÖzyar, Enis
dc.contributor.authorÇorapcıoğlu, Funda
dc.contributor.authorKöksal, Yavuz
dc.contributor.authorAydın, Burca
dc.contributor.authorYazıcı, Nalan
dc.contributor.authorAkyüz, Canan
dc.date.accessioned2020-03-26T17:39:35Z
dc.date.available2020-03-26T17:39:35Z
dc.date.issued2009
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPurpose: To evaluate treatment results for pediatric and young adult (aged <21 years) patients with nonmetastatic nasopharyngeal carcinoma treated with neoadjuvant cisplatin + docetaxel and radiotherapy. Methods and Materials: Ten patients with nasopharyngeal carcinoma who received diagnoses between 2004 and 2007 were treated with four cycles of cisplatin 100 mg/m(2) + docetaxel 75 mg/m(2) on Day 1 with premedication every 3 weeks. All patients were treated with fractionated external beam radiotherapy after chemotherapy to a median dose of 59.4 Gy (range, 54-59.4 Gy) to the primary disease and 40 Gy to the supraclavicular field with the clavicles shielded. Five children were monitored with serum EBV DNA quantification at diagnosis, after each cycle of chemotherapy, before radiotherapy, and at follow-up. Results: The median age of the patients was 14 years (range, 9-20 years), with a male:female ratio of 6:4. Stage distribution was as follows: 2 patients had Stage Ilb disease, 2 had Stage III, 4 had Stage IVa, and 2 had Stage IVb disease. After cisplatin+docetaxel chemotherapy 1 patient had a complete response, 5 had a partial response, 3 had stable disease, and I had disease progression. The 2-year overall survival rate in our series was 90% and the event-free survival rate was 70%. No major chemotherapy toxicity was observed. The EBV DNA titers were higher in 2 of the 5 monitored patients at the time of diagnosis. Conclusion: As neoadjuvant chemotherapy before radiotherapy, the cisplatin+docetaxel combination is safe for use in the treatment of childhood nasopharyngeal carcinoma. (C) 2009 Elsevier Inc.en_US
dc.identifier.doi10.1016/j.ijrobp.2008.05.028en_US
dc.identifier.endpage1120en_US
dc.identifier.issn0360-3016en_US
dc.identifier.issn1879-355Xen_US
dc.identifier.issue4en_US
dc.identifier.pmid18786778en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1116en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.ijrobp.2008.05.028
dc.identifier.urihttps://hdl.handle.net/20.500.12395/23749
dc.identifier.volume73en_US
dc.identifier.wosWOS:000264257400024en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherELSEVIER SCIENCE INCen_US
dc.relation.ispartofINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectChildrenen_US
dc.subjectCisplatinen_US
dc.subjectDocetaxelen_US
dc.subjectNasopharyngeal carcinomaen_US
dc.subjectTreatmenten_US
dc.titlePEDIATRIC AND YOUNG ADULT NASOPHARYNGEAL CARCINOMA PATIENTS TREATED WITH PRERADIATION CISPLATIN AND DOCETAXEL CHEMOTHERAPYen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu